Szemészet, 2020 (157. évfolyam, 1-4. szám)

2020-03-01 / 1. szám

Treatment of dry eye disease: guidelines and future perspectives

oral omega-3 and dry eye syndrome. Ophthalmology 2013; 120: 2191-6.

33. Kinoshita S, Awamura S, Nakamichi N, et al. A multicenten open-label, 52-week study of 2% rebamipide C0PC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014; 157: 576-83.

34. Knop E. Knop N, Millar T, et al. The InternationalWorkshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. Invest Ophthalmol Vis Sei 2011; 52: 1938-1978.

35. Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea 2013; 32: 1219-23.

36. Lau OC, Samarawickrama C, Skalicky SE. P2Y2 receptor agonists for the treatment of dry eye disease: a review. Clin Ophthalmol 2014; 8: 327-34.

37. Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology 2006; 113: 198-205.

38. Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 2016; 26: 287-96.

39. Liu L, Hartwig D, Harloff S, Herminghaus R Wedel T, Kasper K, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest Ophthalmol Vis Sei 2006; 47(6): 2438e44.

40. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-25.

41. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Safety 2002; 25: 33-55.

42. Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011; 1: 154-88.

43. Olenik A, Jimenez-Alfaro I, Alejandre-Alba N, Mahillo-Fernandez I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging 2013; 8: 1133-8.

44. Panagopoulos A, Chalioulias K, Ramsay AS. 'Punctal switch1 grafting for the treatment of dry eyes: our experience. Ophthalmic Res 2011; 46: 218-20.

45. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf 2016; 14: 207-15.

46. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 2008; 27: 64-9.

47. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, doublemasked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004; 138: 444-57.

48. Pokupec R, Petricek I, Sikic J, Bradic M, Popovic-Suic S, Petricek G. Comparison of local acetylcysteine and artificial tears in the management of dry eye syndrome. Acta Med Croat 2005; 59: 337e40.

49. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev 2016; 2: CD009729.

50. Qin J, Zhang L, Cai ZG, et al. Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. Br J Ophthalmol 2013; 97: 1123-8.

51. Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol 1975; 93: 1039-43.

52. Salem DA, El-Shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermectin in comparison with ivermectinmetronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis 2013; 17: e343-7.

53. Sail K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-9.

54. Schräge N, Frentz M, Spoeler F The Ex Vivo Eye Irritation Test (EVEIT! in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1333-40.

55. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011; 111: 5922-43.

56. Shigeyasu C, Hirano S, Akune Y, Yamada M. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects. Curr Eye Res 2015; 40: 878-83.

57. Shine WE, McCulley JP Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003; 76: 417-20.

58. Simopoulos AP The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002; 56: 365-79.

59. Sohrab M, Abugo U, Grant M, Merbs S. Management of the eye in facial paralysis. Facial Plast Surg 2015; 31: 140-4.

60. Sun Y, Zhang R, Gadek TR, O'Neill CA, Pearlman E. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther 2013; 29: 395-402.

61. Ta CN, Shine WE, McCulley JR Pandya A, Trattler W, Norbury JW. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003; 22: 545-8.

62. Tauber J, Karpecki P Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology 2015; 122: 2423-31.

63. TFOS DEWS Report. 2007 Report of the International Dry Eye Workshop. Ocul Surf 2007; 5: 65-204.

64. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999; 83: 390-5.

65. Vasquez LM, Medel R. Lagophthalmos after facial palsy: current therapeutic options. Ophthalmic Res 2014; 52: 165-9.

66. Vegunta S, Patel D, Shen JF Combination Therapy of Intense Pulsed Light Therapy and Meibomian Gland Expression (IPL/MGX) Can Improve Dry Eye Symptoms and Meibomian Gland Function in Patients With Refractory Dry Eye: A Retrospective Analysis. Cornea 2016; 35(3): 318e22.

67. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114: 76-9.

68. Yazici B, Zhao YE, Wu LP Hu L, Xu JR. Association of blepharitis with Demodex: a meta-analysis. Ophthalmic Epidemiol 2012; 19: 95-102.

69. Ziakas NG, Boboridis KG, Terzidou C et al. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Exp Ophthalmol 2010; 38: 683-7.

Levelezési cím

Dn Tóth-Molnár Edit, Szegedi Tudományegyetem, Szemészeti Klinika 6720 Szeged, Korányi Fasor 10-11. E-mail: tme@tmedit.hu